INOVIO is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to treat or prevent disease. We have a deep clinical pipeline with multiple potential near- and mid-term catalysts, including a Biologics License Application (BLA) currently under FDA review for lead candidate INO-3107 for the treatment of Recurrent Respiratory Papillomatosis (RRP), a rare HPV-related disease of the respiratory tract, as well as other late stage HPV-related and oncology candidates. Our next-generation therapeutic candidates are poised to further unlock the potential of DNA medicine technology.
Our versatile platform enables tailored and sustained protein expression within the body with a range of applications including generating T cells to target specific cancers or viral infections, producing monoclonal antibodies for disease prevention or treatment, or achieving therapeutic levels of protein expression for disease control in enzyme or protein replacement diseases. Our proprietary investigational CELLECTRA® devices are designed to deliver DNA medicines into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors.